Bortezomib Mylan

Страна: Нова Зеландия

Език: английски

Източник: Medsafe (Medicines Safety Authority)

Активна съставка:

Bortezomib 3.5mg (as a bortezomib mannitol boronic ester)

Предлага се от:

Viatris Limited

INN (Международно Name):

Bortezomib 3.5 mg (as a bortezomib mannitol boronic ester)

дозиране:

3.5 mg

Лекарствена форма:

Powder for injection

Композиция:

Active: Bortezomib 3.5mg (as a bortezomib mannitol boronic ester) Excipient: Mannitol Nitrogen

Вид предписание :

Prescription

Произведено от:

Laurus Labs Limited

Терапевтични показания:

Bortezomib Mylan in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. Bortezomib Mylan as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. Bortezomib Mylan is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Каталог на резюме:

Package - Contents - Shelf Life: Vial, glass, 10ml Type I with rubber closure and flip-off aluminium seal - 1 dose units - 24 months from date of manufacture stored at or below 25°C protect from light 12 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)

Дата Оторизация:

2015-12-08